TY - JOUR
T1 - Immune adjuvant effect of juzentaihoto, a Japanese traditional herbal medicine, on tumor vaccine therapy in a mouse model
AU - Takeno, Nobuhiro
AU - Inujima, Akiko
AU - Shinohara, Kanna
AU - Yamada, Miyuki
AU - Shibahara, Naotoshi
AU - Sakurai, Hiroaki
AU - Saiki, Ikuo
AU - Koizumi, Keiichi
PY - 2015/12
Y1 - 2015/12
N2 - Used to improve the general physical condition after surgery and to mitigate the side effects of radiation and chemotherapy in tumor patients. Juzentaihoto (JTT) consists of ten medical herbs, and is also called Shi-Quan-Da-Bu-Tang in Chinese herbal medicine. Among Kampo medicines, JTT has especially gained attention as a biological response modifier. Currently, clinical trials of various tumor vaccine therapies are being performed world-wide. However, tumor antigens that are inoculated as vaccines do not have high immunogenicity; thus, it is difficult to obtain an effective therapeutic effect. Thus, it is necessary to develop a tumor vaccine adjuvant that is more potent and very safe. In the present study, we examined the efficacy of JTT as an oral adjuvant when given together with tumor vaccines. As a result, JTT enhanced the phagocytic ability of OVA antigen and the presentation ability of OVA antigen in dendritic cells in vitro. Furthermore, tumor growth was markedly decreased, and the survival period was significantly prolonged in mice inoculated with mouse lymphoma, which is expressed with tumor model antigen. In conclusion, these findings suggest that JTT can be used with tumor vaccines as an immune adjuvant.
AB - Used to improve the general physical condition after surgery and to mitigate the side effects of radiation and chemotherapy in tumor patients. Juzentaihoto (JTT) consists of ten medical herbs, and is also called Shi-Quan-Da-Bu-Tang in Chinese herbal medicine. Among Kampo medicines, JTT has especially gained attention as a biological response modifier. Currently, clinical trials of various tumor vaccine therapies are being performed world-wide. However, tumor antigens that are inoculated as vaccines do not have high immunogenicity; thus, it is difficult to obtain an effective therapeutic effect. Thus, it is necessary to develop a tumor vaccine adjuvant that is more potent and very safe. In the present study, we examined the efficacy of JTT as an oral adjuvant when given together with tumor vaccines. As a result, JTT enhanced the phagocytic ability of OVA antigen and the presentation ability of OVA antigen in dendritic cells in vitro. Furthermore, tumor growth was markedly decreased, and the survival period was significantly prolonged in mice inoculated with mouse lymphoma, which is expressed with tumor model antigen. In conclusion, these findings suggest that JTT can be used with tumor vaccines as an immune adjuvant.
KW - Immune adjuvant
KW - Japanese traditional herbal medicine
KW - Juzentaihoto
KW - Tumor vaccine
UR - http://www.scopus.com/inward/record.url?scp=84982659152&partnerID=8YFLogxK
U2 - 10.3892/ijo.2015.3208
DO - 10.3892/ijo.2015.3208
M3 - 学術論文
C2 - 26496932
AN - SCOPUS:84982659152
SN - 1019-6439
VL - 47
SP - 2115
EP - 2122
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 6
ER -